Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

SAN DIEGO, Nov. 7, 2013 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced third quarter and year-to-date operating results for 2013.  The company will host a conference call today to discuss financial results for the third quarter and year-to-date, and to provide an operational update on developments in the quarter.

"We are pleased to have made good progress toward our goals during the third quarter, moving forward in the development of our lead drug candidate, quizartinib.  We are excited about the upcoming events at ASH in December, where we will have the opportunity to present data from our most recent studies," said Michael Martino, Ambit's president and Chief Executive Officer. "As we head into the last quarter of 2013, we are looking forward to feedback from our upcoming FDA meeting in November and we will provide an update on our development and regulatory plans for quizartinib following that meeting.  Additionally, we remain on track to start our Phase 3 trial in early-2014, as previously guided."

Operational Update
The Company is pleased to announce the acceptance of four abstracts with preliminary data highlighting the Company's lead drug candidate, quizartinib.  Presentations of the final data and two additional posters will be presented during the ASH 55th Annual Meeting at the Ernest Morial Convention Center in New Orleans, LA on December 9, 2013.  Oral presentations include the following:

Results of Phase 2 Randomized, Open-Label, Study of Lower Doses of Quizartinib in Subjects with FLT3-ITD Positive Relapsed Acute Myeloid Leukemia (AML):  The purpo
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... LifeCell Dx and its founder, Dr. Lani ... Advanced Semen Analysis before they do anything else about ... risk factors for struggling couples.Too often, the traditional path ... the infertility. Infertility is fairly equally divided between the ... least complicated and inexpensive analysis that provides far more ...
(Date:3/5/2015)... DIEGO and TORONTO , ... TSX: APS), a clinical-stage company developing new therapeutics and ... today announced that William G. Rice , Ph.D., ... the upcoming 27th Annual ROTH Conference on Tuesday, March ... The Ritz Carlton, Laguna Niguel, CA. ...
(Date:3/5/2015)... (UK) (PRWEB) March 05, 2015 The ... polymer have received the CE mark (European) approval. The ... European Free Trade Association (EFTA) and the European Union. ... has now been granted to implants supplied by the ... spinal conditions. , Osimplant's Cervical Expandable Bladed HA ...
(Date:3/4/2015)... BROOKLYN, N.Y. , March 4, 2015  Brooklyn ... treat their acute and chronic pain and injuries. ... to announce the grand opening of his NJS Physical ... NY on Thursday, March 5, 2015. Health ... the facility, which is located at 1178 Flatbush Avenue. ...
Breaking Biology Technology:LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... Ferring Pharmaceuticals Inc.,has announced that its hyaluronic ... the title sponsor of the EUFLEXXA National,Senior Games ... Year,Award., "This is such a tremendous opportunity ... Alex Drigan, Product Manager, EUFLEXXA(TM). "We,support all that ...
... MOUNTAIN VIEW, Calif., Jan. 28 Clontech Laboratories,Inc., ... announced the,imminent (February 20, 2008) release of its ... issue of Clontechniques, the company,s quarterly,newsletter. Based on ... Stanford, the ProteoTuner systems use a unique technology ...
... for Continued Development of CNDO103 as ... ... today,announced the publication of data demonstrating that the Bcl-2 inhibitor,Apogossypol, effectively ... than Gossypol in vivo in mice., Published online in Blood ...
Cached Biology Technology:Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 2Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 3Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 4Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems 2Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models 2Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models 3
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... ( http://www.nxt-id.com/ ) as part of its 2015 marketing ... Company launched its new consumer website for Wocketwallet.com earlier ... CEO of NXT-ID said, "Our new corporate website naturally ...
(Date:2/5/2015)... 28, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... Global Online CEO Conference on January 29 th ... Pereira , CEO of NXT-ID will present and host ... Wocket smart wallet and its full suite of biometric ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... international team of Australian and Israeli researchers has discovered ... sex event on Earth., An ancient light-sensitive gene has ... Excellence for Coral Reef Studies (CoECRS) that appears to ... of corals across a third of a million square ...
... new method of constructing artificial plant chromosomes from small ... to transport multiple genes at once into embryonic plants ... and passed on to the next generation -- a ... In the October 19, 2007, issue of ...
... Can America really cope with inevitable climate change" ... forestry and fisheries to insurance, construction and tourism -- ... hit hardest, and how" And where will these groups ... they need to make decisions for the uncertain decades ...
Cached Biology News:Key found to moonlight romance 2Key found to moonlight romance 3Transgenics transformed 2Transgenics transformed 3Meeting real-world climate information needs of business, government 2
Freeze 'N Squeeze DNA gel extraction spin columns use a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. Supplied as 25 columns....
The SmartSpec printer paper is used to record data generated by the SmartSpec Plus spectrophotometer. Supplied as 5 packs....
The thermal printer, 120 V, is used to record fluorescence data acquired with the VersaFluor fluorometry systems. The printer includes a cable and power adaptor....
The Econo gradient pump rack is a preassembled rack that is used to hold the components of the Econo gradient pump kits....
Biology Products: